Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01997840Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2014
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ricolinostat in multiple myeloma (MM), sponsored by Celgene Corporation. Started Mar 2014; status: terminated.
02
Drugs
ricolinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01997840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01997840.